Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
出版年份 2018 全文链接
标题
Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
作者
关键词
-
出版物
Cancers
Volume 10, Issue 10, Pages 342
出版商
MDPI AG
发表日期
2018-09-21
DOI
10.3390/cancers10100342
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
- (2018) Hamid Maadi et al. BMC CANCER
- Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade
- (2018) Cecile A.W. Geuijen et al. CANCER CELL
- Treatment of advanced HER2-positive breast cancer: 2018 and beyond
- (2018) Noam Pondé et al. CANCER TREATMENT REVIEWS
- Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors
- (2018) Diego Sanchez-Martinez et al. Theranostics
- Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer
- (2017) Jack Patrick Gleeson et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearance
- (2017) Migyeong Jo et al. mAbs
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Augmentation of antibody-dependent cellular cytotoxicity with defucosylated monoclonal antibodies in patients with GI-tract cancer
- (2017) Takahiro Nakajima et al. Oncology Letters
- Epidermal Growth Factor Receptor Inhibitors: Coming of Age
- (2017) Amit Mahipal et al. Cancer Control
- Pertuzumab and trastuzumab: the rationale way to synergy
- (2016) SANDRINE RICHARD et al. ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
- The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
- (2016) Jennifer L. Hsu et al. CANCER AND METASTASIS REVIEWS
- TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
- (2016) María F. Mercogliano et al. CLINICAL CANCER RESEARCH
- Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment
- (2016) Guowei Gu et al. CURRENT OPINION IN PHARMACOLOGY
- Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes
- (2016) Nishant Mohan et al. MOLECULAR CANCER THERAPEUTICS
- X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity
- (2016) M K Evans et al. Cell Death & Disease
- A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells
- (2016) Hilal S. Khalil et al. Oncotarget
- An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
- (2016) Caroline Jochems et al. Oncotarget
- A Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor
- (2015) Erika Kovacs et al. Annual Review of Biochemistry
- Targeting HER2 for the Treatment of Breast Cancer
- (2015) Mothaffar F. Rimawi et al. Annual Review of Medicine
- Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway
- (2015) Sharon T. Wilks BREAST
- Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast cancer
- (2015) Callie R. Merry et al. BREAST CANCER RESEARCH AND TREATMENT
- A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer
- (2015) Otília Menyhart et al. CURRENT CANCER DRUG TARGETS
- Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages
- (2015) Yun Shi et al. JOURNAL OF IMMUNOLOGY
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells
- (2015) RIKI OKITA et al. ONCOLOGY REPORTS
- Molecular architecture of the ErbB2 extracellular domain homodimer
- (2015) Shi Hu et al. Oncotarget
- Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
- (2015) Martina Di Modica et al. Oncotarget
- A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib
- (2014) N. Elster et al. BREAST CANCER RESEARCH AND TREATMENT
- Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition
- (2014) Milos Dokmanovic et al. CANCER BIOLOGY & THERAPY
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
- (2014) N. A. O'Brien et al. CLINICAL CANCER RESEARCH
- Emerging EGFR antagonists for breast cancer
- (2014) Ana Lluch et al. EXPERT OPINION ON EMERGING DRUGS
- P95 HER2 fragments and breast cancer outcome
- (2014) Deniz Tural et al. Expert Review of Anticancer Therapy
- Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic
- (2014) Alessandra Fabi et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy
- (2014) Alexey Goltsov et al. Cells
- Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer
- (2013) Leticia De Mattos-Arruda et al. ADVANCES IN THERAPY
- HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
- (2013) Allan Lipton et al. BREAST CANCER RESEARCH AND TREATMENT
- Oncogenic ERBB3 Mutations in Human Cancers
- (2013) Bijay S. Jaiswal et al. CANCER CELL
- Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3
- (2013) Malgorzata Magdalena Sak et al. CARCINOGENESIS
- Cellular Functions Regulated by Phosphorylation of EGFR on Tyr845
- (2013) Ken-ichi Sato INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
- (2013) Branka Petricevic et al. Journal of Translational Medicine
- The ErbB/HER family of protein-tyrosine kinases and cancer
- (2013) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcγRIIa Affinity and Selectivity
- (2012) Sang Taek Jung et al. ACS Chemical Biology
- Role of epidermal growth factor receptor in breast cancer
- (2012) Hiroko Masuda et al. BREAST CANCER RESEARCH AND TREATMENT
- Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
- (2012) A Gallardo et al. BRITISH JOURNAL OF CANCER
- Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
- (2012) A H Sims et al. BRITISH JOURNAL OF CANCER
- Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
- (2012) C. Garcia-Garcia et al. CLINICAL CANCER RESEARCH
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- Immune Effects of Trastuzumab
- (2012) Marianna Nuti et al. Journal of Cancer
- Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells
- (2012) Timothy Kute et al. OncoImmunology
- PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
- (2011) J. D. Jensen et al. ANNALS OF ONCOLOGY
- Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells
- (2011) Jayashree P. Joshi et al. BIOCHEMICAL PHARMACOLOGY
- Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
- (2011) E. Razis et al. BREAST CANCER RESEARCH AND TREATMENT
- Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
- (2011) R. Ghosh et al. CANCER RESEARCH
- Function ofERBB4is determined by alternative splicing
- (2011) Ville Veikkolainen et al. CELL CYCLE
- Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
- (2011) Y. Yamashita-Kashima et al. CLINICAL CANCER RESEARCH
- Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies
- (2011) D. Faratian et al. CLINICAL CANCER RESEARCH
- Up-regulation ofmiR-21Mediates Resistance to Trastuzumab Therapy for Breast Cancer
- (2011) Chang Gong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
- (2011) Naoki Niikura et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- PTEN, PIK3CA, p-AKT, and p-p70S6K Status
- (2010) Francisco J. Esteva et al. AMERICAN JOURNAL OF PATHOLOGY
- Fc R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
- (2010) K. Tamura et al. ANNALS OF ONCOLOGY
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway
- (2010) Rita Nahta et al. Clinical Breast Cancer
- Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients
- (2010) J. Sperinde et al. CLINICAL CANCER RESEARCH
- Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers
- (2010) Bhuvanesh Dave et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy
- (2010) Kan Yonemori et al. JOURNAL OF SURGICAL ONCOLOGY
- ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
- (2010) Fumin Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting erbB receptors
- (2010) Zheng Cai et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
- (2010) Merel Gijsen et al. PLOS BIOLOGY
- Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
- (2009) Y. Kataoka et al. ANNALS OF ONCOLOGY
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
- (2009) G. Zhuang et al. CANCER RESEARCH
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment
- (2009) Jaume Capdevila et al. CANCER TREATMENT REVIEWS
- Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
- (2009) E. A. Mittendorf et al. CLINICAL CANCER RESEARCH
- ErbB receptors and signaling pathways in cancer
- (2009) Nancy E Hynes et al. CURRENT OPINION IN CELL BIOLOGY
- ADAM17 as a Therapeutic Target in Multiple Diseases
- (2009) Joaquin Arribas et al. CURRENT PHARMACEUTICAL DESIGN
- Potential of ErbB4 antibodies for cancer therapy
- (2009) Maija Hollmén et al. Future Oncology
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2009) Neil L. Spector et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review
- (2009) Shaheenah Dawood et al. JOURNAL OF CLINICAL ONCOLOGY
- A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis
- (2009) K. Pedersen et al. MOLECULAR AND CELLULAR BIOLOGY
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Structure-Based View of Epidermal Growth Factor Receptor Regulation
- (2008) Kathryn M. Ferguson Annual Review of Biophysics
- System-wide Investigation of ErbB4 Reveals 19 Sites of Tyr Phosphorylation that Are Unusually Selective in Their Recruitment Properties
- (2008) Alexis Kaushansky et al. CHEMISTRY & BIOLOGY
- Ligand-induced ErbB receptor dimerization
- (2008) Mark A. Lemmon EXPERIMENTAL CELL RESEARCH
- EGFR family: Structure physiology signalling and therapeutic targets†
- (2008) Antony W. Burgess GROWTH FACTORS
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- HER4 Intracellular Domain (4ICD) Activity in the Developing Mammary Gland and Breast Cancer
- (2008) Frank E. Jones JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
- (2008) M Scaltriti et al. ONCOGENE
- Functional selectivity of EGF family peptide growth factors: Implications for cancer
- (2008) Kristy J. Wilson et al. PHARMACOLOGY & THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search